Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
As of close of business last night, Harvard Bioscience Inc’s stock clocked out at $0.42, up 3.87% from its previous closing price of $0.41. In other words, the price has increased by $3.87 from its previous closing price. On the day, 5.7 million shares were traded.
Ratios:
To gain a deeper understanding of HBIO’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.35 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 48.98. For the most recent quarter (mrq), Quick Ratio is recorded 0.40 and its Current Ratio is at 0.81. In the meantime, Its Debt-to-Equity ratio is 3.01 whereas as Long-Term Debt/Eq ratio is at 0.49.
On March 10, 2023, The Benchmark Company Upgraded its rating to Buy which previously was Speculative Buy and also upped its target price recommendation from $3 to $4.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 13 ’24 when Green James W bought 10,000 shares for $2.91 per share. The transaction valued at 29,100 led to the insider holds 3,111,091 shares of the business.
Green James W bought 20,000 shares of HBIO for $61,400 on Jun 06 ’24. The Chief Executive Officer now owns 3,101,091 shares after completing the transaction at $3.07 per share.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 0.20 while its Price-to-Book (P/B) ratio in mrq is 1.26.
Stock Price History:
Over the past 52 weeks, HBIO has reached a high of $3.60, while it has fallen to a 52-week low of $0.28. The 50-Day Moving Average of the stock is 2.65%, while the 200-Day Moving Average is calculated to be -74.58%.
Shares Statistics:
A total of 44.21M shares are outstanding, with a floating share count of 37.41M. Insiders hold about 15.39% of the company’s shares, while institutions hold 58.64% stake in the company.
Earnings Estimates
The current rating of Harvard Bioscience Inc (HBIO) reflects the combined expertise of 2.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is $0.01, with high estimates of $0.03 and low estimates of $0.0.
Analysts are recommending an EPS of between $0.05 and $0.02 for the fiscal current year, implying an average EPS of $0.04. EPS for the following year is $0.06, with 2.0 analysts recommending between $0.08 and $0.04.
Revenue Estimates
In the current quarter, 2 analysts expect revenue to total $18.75M. It ranges from a high estimate of $19.5M to a low estimate of $18M. As of the current estimate, Harvard Bioscience Inc’s year-ago sales were $23.1MFor the next quarter, 2 analysts are estimating revenue of $21.5M. There is a high estimate of $21.5M for the next quarter, whereas the lowest estimate is $21.5M.
A total of 2 analysts have provided revenue estimates for HBIO’s current fiscal year. The highest revenue estimate was $87M, while the lowest revenue estimate was $86M, resulting in an average revenue estimate of $86.5M. In the same quarter a year ago, actual revenue was $94.14MBased on 2 analysts’ estimates, the company’s revenue will be $95.15M in the next fiscal year. The high estimate is $95.8M and the low estimate is $94.5M.
